Sign up Australia
Proactive Investors - Run By Investors For Investors

Ellex Medical Lasers has support for its macular degeneration treatment

Ellex Medical Lasers has support for its macular degeneration treatment

Ellex Medical Lasers (ASX:ELX) has announced additional scientific research validating the method of action of the company’s proprietary Retinal Rejuvenation Therapy (2RT) for the treatment of early age-related macular degeneration.

Research found that directly following treatment by 2RT of the targeted retinal pigment epithelium (RPE) cells, the surrounding, surviving cells grew into the vacated spaces and stimulated expression of a range of protein factors, triggering a regenerative effect on nearby RPE cells.

This confirmed the positive cellular response induced by 2RT, validating its previously postulated method of action.

It offers the potential for 2RT to emerge as a platform technology that could provide additional, alternative therapeutic applications.

The research is expected to be published in a peer-review publication during the 2016 financial year.



Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

View full ELX profile View Profile

Ellex Medical Lasers Timeline

Newswire
November 30 2016

Related Articles

1511901712_biotech_517925923.jpg
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
profit meter
April 02 2018
Having secured US$6.9mln of new investment, the company is now primed for growth
Harley Street sign
December 07 2017
The injection will bankroll the continuing technical development of the firm’s first LIGHT system and its installation at the Harley Street Proton Therapy Centre

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use